-
The Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Study compared two doses of dabigatran, a direct thrombin inhibitor, with warfarin for the prevention of stroke and systemic emboli in patients with nonvalvular atrial fibrillation (AF).
-
Aspirin and cancer prevention; rivaroxaban for pulmonary embolism; new rhinosinusitis practice guidelines; and FDA actions.
-
This paper reports registry data from a large, single-center patient cohort with myotonic dystrophy type 1 (DM1). Between January 2000 and December 2009, 914 adult patients were included in the DM1 Heart Registry at the authors' institution.
-
Various risk schemes have been promulgated for assessing the risk of stroke and bleeding in patients with atrial fibrillation (AF). These investigators used the Swedish Atrial Fibrillation cohort study to investigate the comparative utility of four schemes that have been validated in AF cohorts: CHADS2, CHA2DS2-VASc, HAS-BLED, and HEMORR2HAGES.
-
Angiotensin-converting enzyme inhibitor (ACEI) therapy may be beneficial during coronary artery bypass graft (CABG) surgery because of its anti-inflammatory and other vascular benefits.
-
This paper discusses the clinical utility of impulse and rotor mapping to guide atrial fibrillation (AF) ablation and is a follow-up to the acute observations discussed in Clinical Cardiology Alert several months ago.1 The authors hypothesized that AF is sustained by localized sources that may be targeted during AF ablation procedures.
-
Side effects of finasteride; new ruling on pharmaceutical companies paying generic manufacturers; and FDA actions.
-
Primary percutaneous coronary intervention (PCI) saves lives in patients suffering from ST-elevation myocardial infarction (STEMI).
-
In this paper, the authors perform a systematic review and meta-analysis of published reports comparing anticoagulation management strategies around the time of cardiac rhythm device implantation. Using standard techniques, the authors searched the medical literature and identified studies that assessed two or more anticoagulation strategies around the time of cardiac rhythm device implantation.
-